Healthcare

Nova Eye Medical (ASX:EYE) Surges Ahead with Record FY25 Revenues
July 08, 2025 06:25 PM AEST| By Team Kalkine MediaHighlights,Nova Eye Medical reports record FY25 revenue performance,Significant uplift in US market sales drives growth,H2FY25 shows strong momentum across operations,Nova Eye Medical (ASX:EYE) has released its full-year financial results for FY25, s...

Cannabinoid Therapy Steps Up in Slovenia: Argent BioPharma (ASX:RGT) Expands Epilepsy Treatment Reach
July 08, 2025 06:15 PM AEST| By Team Kalkine MediaHighlights,Argent BioPharma expands cannabinoid epilepsy treatment in Slovenia,Successful pilot leads to routine hospital use,Multi-year regulatory collaboration drives clinical adoption,Argent BioPharma (ASX:RGT) has taken a significant step forward...

Sofdra™ Gains Traction: Botanix Pharmaceuticals (ASX:BOT) Reports Positive Growth Momentum
July 08, 2025 05:53 PM AEST| By Team Kalkine MediaHighlights,Sofdra™ shows steady monthly growth post-launch,Over 16,000 prescriptions filled since February,Expansion into new sales territories underway,Botanix Pharmaceuticals (ASX:BOT) has unveiled strong early-stage performance metrics for its der...

PME’s Growth Momentum: Key Insights into This ASX 100 Radiology Software Leader
July 08, 2025 05:43 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus demonstrates robust profit and revenue growth,Strong balance sheet supports operational resilience,Return on equity reflects high capital efficiency,Pro Medicus (ASX:PME), a prominent medical imaging software provider, has made...

Monash IVF (ASX:MVF) Attracts Market Buzz Despite Recent Setback
July 08, 2025 04:49 PM AEST| By Team Kalkine MediaHighlights,Monash IVF (MVF) under focus after operational mishap,Adjusted financial outlook reflects anticipated market share shifts,Sector valuation hints at consolidation prospects,Monash IVF (ASX:MVF), a prominent name in Australia’s fertility ser...

CSL (ASX:CSL) Share Price Under Watch: Exploring the Resilience of a Leading Healthcare Stock in the ASX 300 Index
July 07, 2025 06:29 PM AEST| By Team Kalkine MediaHighlights,CSL operates across plasma, flu vaccine, and renal care segments,Part of the ASX 300 Index, reflecting its position among Australia’s largest listed entities,Healthcare demand continues to show global momentum,CSL Ltd (ASX:CSL) remains a p...

Nanosonics (ASX:NAN) Elevates Infection Prevention with trophon3 Launch
July 07, 2025 04:46 PM AEST| By Team Kalkine MediaHighlights,Nanosonics unveils trophon3 with faster disinfection and digital integration,trophon2 Plus software upgrade brings advanced features to existing systems,Launch extends across multiple regions; FDA review in progress,Nanosonics (ASX:NAN), a...

CSL Ltd (ASX:CSL) Strengthens Healthcare Footprint in ASX Top 300
July 04, 2025 07:41 PM AEST| By Team Kalkine MediaHighlights,CSL Ltd is a key healthcare company in the ASX Top 300 and ASX 100,Business operations include plasma therapies, flu vaccines, and kidney treatments,Regular payouts place CSL under asx dividend stocks,CSL Ltd (ASX:CSL) is listed under the,...

Orthocell's Remplir Drives Record Quarterly Revenue Surge on Expanding Hospital Adoption
July 04, 2025 03:13 PM AEST| By Team Kalkine MediaHighlights,Record A$2.73 million quarterly revenue,Over 206 surgeons now using Remplir in 166+ hospitals,US expansion set to accelerate future momentum,Orthocell Ltd (ASX:OCC) has reported a record-breaking revenue performance for the June 2025 quart...

ASX 200 Health Sector Lags but Amplia and Biotech Peers Shine in June
July 04, 2025 02:16 PM AEST| By Team Kalkine MediaHighlights,ASX 200 Health Care sector underperforms broader index despite isolated stock rallies,Amplia Therapeutics records complete cancer responses in ACCENT trial,Neuro and radiopharma companies advance on clinical updates and acquisitions,The,AS...

Imugene Advances Cancer Trials with Fresh Funding and Clinical Progress
July 04, 2025 02:14 PM AEST| By Team Kalkine MediaHighlights,Imugene receives A$5.87M in R&D tax refund for 2024.,Initiates Phase II dosing for colorectal cancer therapy.,Secures key US patent for onCARlytics platform,Imugene Ltd (ASX:IMU) has taken notable strides in advancing its immuno-oncology p...

CSL and Endeavour Shine as Value Picks in ASX 100 Near Highs
July 04, 2025 01:25 PM AEST| By Team Kalkine MediaHighlights,CSL Ltd remains focused on growth despite ongoing share price pressure,Endeavour Group continues to maintain market presence through retail network strength,Both companies are listed on the,ASX 100,and trade below recent highs,With the,S&P...

ASX 300: PTX-100 Advances in Clinical Trials as Prescient Therapeutics Strengthens Biotech Footprint
July 04, 2025 01:21 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics progresses PTX-100 into Phase 2a trials following favourable outcomes in early-stage testing,The company receives US FDA orphan drug and fast track designations for CTCL treatment,PTX-100 shows encouraging tolerance...

CSL’s Growth Outlook Amid Share Price Pressure: A Deep Dive into the ASX Giant
July 04, 2025 10:55 AM AEST| By Team Kalkine MediaHighlights,CSL (CSL) has seen a notable share price dip in 2025,Consistent financial growth across revenue, margin, and profitability,Maintains strong positioning among ASX 100 companies,CSL Limited (ASX:CSL), one of the major players in Australia’s...

ASX 200 | Pro Medicus (ASX:PME) Soars on US Imaging Contracts
July 03, 2025 04:15 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus secures a decade-long imaging contract with US-based UCHealth,Renewal of FMOLHS deal includes new cloud-based imaging deployment,Company reinforces growth in enterprise-wide digital health platforms,Healthcare technology compan...

Prescient Therapeutics Launches Funding Round to Advance Cancer Therapy Trials
July 02, 2025 04:11 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics launches SPP to fund Phase 2 trials,PTX-100 targets rare lymphoma with regulatory support,Shares offered at a discounted 4 cents each,Prescient Therapeutics (ASX:PTX) has officially launched a Share Purchase Plan (SP...

Prescient Therapeutics Opens A$7M Share Plan to Accelerate Cancer Therapy Trials
July 02, 2025 03:53 PM AEST| By Team Kalkine MediaHighlights,Prescient (ASX:PTX) launches A$7M Share Purchase Plan,Funds directed toward Phase 2 trials of targeted cancer therapy PTX-100,PTX-100 holds Orphan Drug and Fast Track status from US FDA,Prescient Therapeutics (ASX:PTX) has initiated a Shar...

Pro Medicus (ASX:PME): A Radiology Powerhouse in the ASX200 Spotlight
July 02, 2025 10:19 AM AEST| By Team Kalkine MediaHighlights,PME share price rises over 11% in 2025 YTD,Radiology software firm gains traction amid digital healthcare growth,ASX200 stock,showcases,strong revenue momentum,Pro Medicus (ASX:PME) has emerged as one of the notable gainers on the ASX in 2...

Prescient Therapeutics ASX:PTX Boosts Oncology Pipeline | All Ordinaries
July 01, 2025 09:58 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics launches Share Purchase Plan to fund PTX-100 Phase 2 development,Funds to support regulatory advancement of first-in-class GGT-1 inhibitor,PTX-100 holds Orphan Drug and Fast Track designations from the US FDA,Prescie...

Prescient Therapeutics (ASX:PTX) Launches SPP to Boost Cancer Therapy Trials | All Ordinaries
July 01, 2025 01:39 PM AEST| By Team Kalkine MediaHighlights,Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development,Proceeds to fund Phase 2 trials in treating relapsed cutaneous T-cell lymphoma,PTX-100 holds FDA Orphan Drug and Fast Track status for advanced cancer...

Advertise your brand on Kalkine Media